Skip to content
SEKISUI XenoTech DD Blog Logo

SEKISUI XenoTech Featured in Fall Issue of NewsWave

Leader in pharmaceutical research and scientific collaboration

Originally printed in the Fall 2017 Issue of NewsWave.

SEKISUI XenoTech, LLC, which is headquartered in Kansas City, KS, was founded in 1994 to provide scientists and pharmaceutical researchers with the finest tools and resources needed to advance the development of safer drugs. SEKISUI XenoTech’s products and contract services optimize the discovery, development, and approval of new therapies worldwide. From a small laboratory at the University of Kansas Medical Center, SEKISUI XenoTech has grown to become a trusted partner and expert consultant to almost every one of the top global pharmaceutical companies, as well as numerous biotechs, smaller or virtual pharma entities, academic institutions and more.

SEKISUI XenoTech’s experience dates back to the 1980s. The KU Medical Center laboratory, that would eventually evolve into SEKISUI XenoTech, was busy doing its own drug metabolism research and making its own cellular test systems for this research. Their research was so well regarded that, after repeated requests from the scientific community, they began to ship their test systems as products to laboratories worldwide and perform contract studies with those products. This respect continues to this day, with the company being requested to present at global industry events, contribute to various publications, and cited in over 2,000 papers and other research.

Our business

SEKISUI XenoTech specializes in providing in vitro drug metabolism and drug-drug interaction (DDI) contract research services to predict, evaluate and explain the DDI potential of new drug candidates prior to or concurrent with human clinical trials, including analyticaldrug transportenzyme inhibition and induction, and related studies. They also continue to sell the tissue and cellular-based test systems that it creates for this research, including a wide range of high-quality, unique and standard reagents, such as subcellular fractionshepatocytes and tissue samples, along with related products including mediacell lines from the Japanese Collection of Research Biosources Cell Bank (JCRB), recombinant enzymessubstrates and metabolites from Cypex, and metabolite production kits from HepatoChem.

XenoTech, LLC was acquired by SEKISUI Medical Co. Ltd in August of 2008 to add the company’s focused expertise on biotransformation and preclinical development, consulting to the broad range of pharmaceutical development services offered by SEKISUI. This alignment has allowed SEKISUI XenoTech to become a global contract research organization (CRO) with unparalleled experience in absorption, distribution, metabolism, and excretion (ADME); drug metabolism and pharmacokinetics (DMPK); and DDI, offering a comprehensive range of services to accelerate drug development from discovery through clinical support, including screeningradiolabeling, active pharmaceutical ingredient (API) manufacturing, in vitro ADME, toxicology and pharmacologyin vivo pre-clinical ADME, toxicology and quantitative whole body autoradiography (QWBA), metabolite ID and productionbioanalytical services, and consulting.

Just as joining SEKISUI’s family has helped SEKISUI XenoTech expand its service offerings, they are also expanding and enhancing their product offerings by deploying new technologies to improve material performance and viability, as well as offering new test systems to meet the changing needs of their clients.

Commitment to social responsibility

SEKISUI XenoTech has also embraced SEKISUI’s commitment to social responsibility. Their CSR effort features the Green Hearts Team, which formed as a sustainability committee in 2014. The Green Hearts Team works on projects that reduce waste, lower energy usage, and increase environmental awareness. The team has hosted webinars, brought in guest speakers, and presented trainings about environmental awareness. One of the efforts that Green Hearts is leading is to achieve zero landfill this fiscal year by steadily changing landfill waste streams over to recycling. Thanks to them, recycling surpassed landfill by the end of FY2015, and has increased its lead since then. They are also working to eliminate energy usage inefficiencies. This reduces SEKISUI XenoTech’s carbon footprint, and lowers fixed costs.

SEKISUI XenoTech’s Employee Recognition Team also sponsors blood drives, charity drives, and community activities. They sponsor an annual Angel Tree where employees buy Christmas presents for less-fortunate kids. The Employee Recognition Team also puts on fundraising events for charity, disaster relief, or disease research.

NewsWave Fall 2017

Learn more about:

About the Authors

Michael Millhollen received his bachelor's degree in Visual Communications from the University of Kansas and has over 20 years of experience in marketing and communications. As Global Marketing Manager, he is dedicated to the objective of sharing SEKISUI XenoTech’s scientific expertise and knowledge with scientists around the world.

Subscribe to our Newsletter

Stay up to date with our news, events and research

In vitro pipette test article treatment

Do you have a question or a request for upcoming blog content?

We love to get your feedback

A scientist utlilizing a microplate